Monitoring the patient on hemodialysis;Monitorización del paciente en hemodiálisis

Nefrologia

Volumn 26, Issue SUPPL.8, 2006, Pages 34-53

  Gonzalez Parra E ^a   Arenas, M D ^a   Valencia, J ^a   Angoso, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; HUMAN; KIDNEY FAILURE; METHODOLOGY; MONITORING; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE; MONITORING, PHYSIOLOGIC; RENAL DIALYSIS; RISK FACTORS;

EID: 38449108105     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (119)

1. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrology Dialysis Transplantation 19 (SUPL. 2), 2004.
2. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial &Transplant 14 (SUPL. 5): 1-50, 1999.
3. NKF-DOQI Work Group: NKF-DOQI clinical practice guidelines for the treatment of anaemia of chronic renal failure. Am J Kidney Dis 30 (SUPL. 3): s192-s240, 1997.
4. Masterclass in Nephrology: Managing renal anaemia: what are the issues in 2003? Nephrol Dial & Transplant 18 (SUPL. 8): viii 1- viii 41, 2003.
5. Locatelli F, Pisoni RL, Combe Ch y cols.: Anemia in hemodialysis patients of five european countries: association with morbidity and mortality in DOPPS: Nephrol Dial Transplant 19: 121-132, 2004.
6. Pérez García R: Spanish survey on anaemia management. Nefrología 23: 300-311, 2003.
7. Portolés J, López JM, Aljama P: Morbidity, mortality and anemia in hemodialysis patients (MAR 1 project). Nefrología 22 (SUPL. 6): S 54, 2002.
8. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: DOQI. Am J Kidney Dis 42: S-12, 2003.
9. European best practice guidelines for haemodialysis: Section VI. Haemodialysis-associated infection. Nephrol Dial Transplant 72-87: 17 (SUPL. 7), 2002.
10. Barril G, González-Parra E, Alcázar R, Arenas MD, Campistol JM, Caramelo C, Carrasco M, Carreño V, Espinosa M, García Valdecasas J, Górriz JL, López MD, Martín L, Ruiz P, Teruel JL: Guías sobre enfermedades víricas en hemodiálisis. Nefrología 24: 43-66, 2004.
11. Bommer J, Ritz E, Andrassy K: Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients. Proc Eur DIAL Transplant Assoc 20: 161-168, 1983.
12. Espinosa M, Martín-Malo A, Álvarez de Lara MA, Soriano S, Aljama P. High ALT levels predict viremia in anti-HCVpositive HD patients if a modified normal range of ALT is applied. Clin Nephrol 54: 151-6, 2000.
13. Centers for Disease Control. Update: Universal precautions for prevention of transmission of human immunodeficiency virus (HIV), hepatitis B virus and ther bloodborne pathogens in heath-care settings. MMWR 37: 377-382, 387-388, 1988.
14. Locatelli F, Fouque D, Heimburger O y cols.: Nutritional status in dialysis patients: a European consensus. Nephrol Dial Trasplant 17: 563-572, 2002.
15. Guías SEN: Riñón y enfermedad cardiovascular. Nefrología 24 (SUPL. 6), 2004.
16. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41 (4 SUPL. 3): I-IV, S1-91, 2003.
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-421, 2002.
18. Viola RA, Abbott KC, Welch PG, McMillan RJ, Sheikh AM, Yuan CM: A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients. BMC Nephrol 3: 9, 2002.
19. Locatelli F, Bommer J, London GM, Martin-Malo A, Wanner C, Yaqoob M, Zoccali C. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant 16 (3). p. 459-68, 2001.
20. Wilson PW, Culleton BF: Epidemiology of cardiovascular disease in the United States. Am J Kidney Dis 32 (5 SUPL. 3), pp. S56-65, 1998.
21. Foley RN, Parfrey PS and Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (5 SUPL. 3), pp. S112-9, 1998.
22. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr.: Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32 (5), pp. 853-906, 1998.
23. Levey AS, Eknoyan G: Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant 14 (4), pp. 828-33, 1999.
24. Bet JA, Bansal VK: Interventions for other risk factors: tobacco use, physical inactivity, menopause, and homocysteine. Am J Kidney Dis 32 (5 SUPL. 3), pp. S172-83, 1998.
25. Kasiske, B.L., Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32 (5 SUPL. 3), pp. S142-56, 1998.
26. Murphy SW, Foley RN, Parfrey PS: Screening and treatment for cardiovascular disease in patients with chronic renal disease. Am J Kidney Dis 32 (5 SUPL. 3), pp. S184-99, 1998.
27. De Santo NG, Cirillo M, Perna A, De Santo LS, Anastasio P, Pollastro MR, De Santo RM, Iorio L, Cotrufo M, Rossi F. The heart in uremia: role of hypertension, hypotension, and sleep apnea. Am J Kidney Dis 38 (4 SUPL. 1), pp. S38-46, 2001.
28. Stam F, Van Guldener C, Ter Wee PM, Jakobs C, De Meer K, Stehouwer CD: Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease. Kidney Int 67: 259-264, 2005.
29. Goodship TH: Fibrinogen in hemodialysis: the worst of both worlds? Kidney Int 63: 379-380, 2003
30. Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales L, Levin NW: Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in hemodialysis patients. Kidney Int 63: 315-322, 2003.
31. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD: A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 15: 442-453, 2004.
32. Giordano M, De Feo P, Lucidi P y cols.: Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. J Am Soc Nephrol 12: 349-354, 2001.
33. Leibovitz E, Hazanov N, Frieman A, Elly I, Gavish D. Atorvastatin reduces fibrinogen levels in patients with severe hypercholesterolemia: additional evidence to support the antiinflammatory effects of statins. Isr Med Assoc J 6: 456-459, 2004.
34. Korevaar JC, Van Manen JG, Dekker FW, De Waart DR, Boeschoten EW, Krediet RT: Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 15: 2916-2922, 2004.
35. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S: Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 43: 471-478, 2004
36. Ikejiri A, Hirano T, Murayama S y cols.: Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism 53: 1113-1117, 2004.
37. Fernández-Reyes MJ, Mon C, Heras M, Guevara P, García MC, Sánchez R, Velasco S, Álvarez-Ude F: Predictive value of troponin T levels for ischemic heart disease and mortality in patients on hemodialysis. J Nephrol 17 (5): 721-7, 2004.
38. Jung HH, Ma KR, Han H. Elevated concentrations of cardiac troponins are associated with severe coronary artery calcification in asymptomatic haemodialysis patients. Nephrol Dial Transplant 19 (12): 3117-23, 2004.
39. Needham DM, Shufelt KA, Tomlinson G, Scholey JW, Newton GE: Troponin I and T levels in renal failure patients without acute coronary syndrome: a systematic review of the literature. Can J Cardiol 20 (12): 1212-8, 2004.
40. Locatelli F, Fouque D, Heimburger O y cols.: Nutritional status in dialysis patients: a European consensus. Nephrol Dial Trasplant 17: 563-572, 2002.
41. Chamberlain IO, Okonofua EC, Nzerue MC y cols.: Role of hypoalbuminemia and hypocholesterolemia as copredictors of mortality in acute reanl failure. Kidney Int 56: 19: 1058-1063, 1999.
42. Steinman T: Serum albumin: Its significance in patients with ESRD. Seminars in Dialysis 13: 404-408, 2000.
43. Bistrian BR, Mc Cowen KC, Chan S: Protein-Energy malnutrition in dialysis patients. Am J Kidney Dis 33: 172-175, 1999.
44. ESRD Performance measure (AJKD Vol 39 Núm 5 SUPL. 2 (May) S4-S61.
45. European Best Practice Guiddelines for haemodialysis. Nephrol Dial & Transplant 17 (SUPL. 7), 2002.
46. http: //www.kidney.org/professionals/kdoqi/guidelines_updates/ nut_appx01a.html 4
47. Geffriaud-Ricouard C, Noel LH, Chauveau D, Houhou S, Grunfeld JP, Lesavre P: Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 39 (3): 125-36, 1993.
48. Pettersson E, Heigl Z: Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. Clin Nephrol 37 (5): 219-28, 1992.
49. Unger J: Amiodarone and thyroid: pharmacologic and toxic effects. Rev Med Brux 17: 203-5, 1996.
50. Bartalena L, Bogazzi F, Brogioni S, Burelli A, Scarcello G, Martino E: Measurement of serum free thyroid hormone concentrations: an essential tool for the diagnosis of thyroid dysfunction. Horm Res 45: 142-7, 1996.
51. Fuks AG, Vaisman M, Buescu A: Thyroid dysfunction and cardiological management in patients receiving amiodarone. Arq Bras Cardiol 82: 523-3, 2004.
52. Mioli VA, Balestra E, Bibiano L, Dellabella S, Fanciulli E, Gaffi G, Perilli A, Petroselli F, Ricciatti AM, Carletti P: Behavior of beta 2-microglobulin (B2-m) serum levels in uremic patients. Int J Artif Organs 17: 576-80, 1994.
53. Ayli D, Ayli M, Azak A, Yuksel C, Kosmaz GP, Atilgan G, Dede F, Abayli E, Camlibel M: The effect of high-flux hemodialysis on renal anemia. J Nephrol 17: 701-6, 2004.
54. Girgis I, Contreras G, Chakko S, Pérez G, McLoughlin J, Lafferty J, Gualberti L, Ammazzalorso M, Constantino T, Bresznyak ML, Kleiner M, McGinn TG, Myerburg RJ: Effect of hemodialysis on the signal-averaged electrocardiogram. Am J Kidney Dis 34 (6): 1105-13, 1999.
55. Cupisti A, Galetta F, Morelli E, Titori G, Sibilia G, Meola M, Barsotti G: Effect of hemodialysis on the dispersion of the QTc interval. Nehron 82 (3): 278-5, 1999.
56. Ichikawa H., Nagake Y., Makino H. Signal averaged electrocardiography (SAECG) in patients on hemodialysis. J Med 28 (3-4): 229-43, 1997.
57. Genovesi S, Rivera R, Fabbrini P, Dossi C, Bonforte G, Mircoli L, Ferrari AU, Stella A, Stramba-Badiale M: Dynamic QT interval analysis in uraemic patients receiving chronic haemodialysis. J Hypertens 21 (10): 1921-6, 2003.
58. Madias JE, Narayan V: Augmentation of the amplitude of electrocardiographic QRS complexes immediately after hemodialysis: a study of 26 hemodialysis sessions of a single patient, aided by measurements of resistance, and impedance. J Electrocardiol 36 (3): 263-71, 2003.
59. Fukuta H, Hayano J, Ishihara S, Sakata S, Mukai S, Ohte N, Ojita K, Yagi K, Matsumoto H, Sohmiya S, Kimura G: Prognostic value of heart rate variability in patients with endstage renal disease on chronic haemodialysis. Nephrol Dial transplant 18 (2): 318-25, 2003.
60. Beaubien ER, Pylypchuk GB, Akhtar J, Biem HJ: Value of corrected QT interval dispersion in identifying patients initiating dialysis al increased risk of total and cardiovascular mortality. Am J Kidney Dis 39 (4): 834-42, 2002.
61. Giordano M, Manzella D, Paolisso G, Caliendo A, Varricchio M, Giordano C: Differences in heart rate variability parameters during the post-dialytic period in type II diabetic and non-diabetic ESRD patients. Nephrol Dial Transplant 16 (3): 566-73, 2001.
62. Madias JE: A comparison of a 2-lead, 6-lead and 12 lead ECGs in patients with changing edematous states: implications of the employment of quantitative electrocardiography in research and clinical applications. Chest 124 (6): 2057-63, 2003.
63. Schmidt A, Stefenelli T, Schuster E, Mayer G: Informational contribution of non-invasive screening test for coronary artery disease in patients on chronic renal replacement therapy. Am J Kidney Dis 37 (1): 56-63, 2001.
64. Lee DK, Marantz PR, Devereux RB, Kligfield P, Alderman MH: Left ventricular hypertrophy in black and white hypertensives. Standard electrocardiographic criteria overestimate racial differences in prevalence. JAMA 267 (24): 3294-9, 1992.
65. Crow RS, Prineas RJ, Rautaharju P, Hannan P, Liebson PR: Relation between electrocardiography and echocardiography for left ventricular mass in mild systemic hypertension (results from treatment of mild hypertension study). Am J Cardiol 75: 1233, 1995.
66. Nakamura S, Sasaki O, Nakahama H, Inenaga T, Kimura G: Left ventricular hypertrophy is a risk factor independent of hypertension in survival of hemodialyzed patients. Ren Fail 24 (2): 175-86, 2002.
67. Nakamura S, Uzu T, Inenaga T, Kimura G: Prediction of coronary artery disease and cardiac events using electrocardiographic changes during hemodialysis. Am J Kidney Dis 36 (3): 592-9, 2000.
68. Narula AS, Jha V, Bali HK, Sakhuja V, Sapru RP: Cardiac arrhytmias and silent myocardial ischemia during hemodialysis. Ren Fail 22 (3): 355-68, 2000.
69. Morris ST, Galiatsou E, Stewart GA, Rodger RS, Jardine AG: QT dispersion before and after hemodialysis. J Am Soc Nephrol 10 (1): 160-3, 1999.
70. Nappi SE, Virtanen VK, Saha HH, Mustonen JT, Pasternack AI: QTc dispersion increases during hemodialysis with lowcalcium dialysate. Kidney Int 57 (5): 2117-22, 2000.
71. Gavelli G, Zompatori M: Thoracic complications in uremia patients and in patients undegoing dialytic treatment: state of the art. Eur Radiol 7 (5): 708-17, 1997.
72. Myers BD, Rubin AE, Schey G, Bruderman I, Pokroy NR, Levi J: Functional characteristics of the lung in chronic uremia treated by renal dialysis therapy. Chest 68 (2): 191-4, 1975.
73. Skov PE, Hansen HE, Spencer ES: Uremic pericarditis. Acta Med Scand 186 (5): 421-8, 1969.
74. Bourquia A, Zaghloul K, Berrada S, Essamadi JE, Ben Youssef S, Zaid D: Ophthalmologic manifestations in patients Ander chronic hemodiálisis. Ann Med Interne (Paris) 143 (5): 351-2, 1992.
75. Narasimhan N, Golper T, Wolfson M y cols.: Clinical characteristics and diagnostic considerations in adquired renal cystic disease. Kidney Int 30 (5): 748-52, 1986.
76. Ishikawa I: Adquired cystic disease: mechanisms and manifestations. Sem Nephrol 11 (6): 671-84, 1991.
77. Ishikawa I, Saito Y, Shikura N y cols.: Ten year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis 16 (5); 452-8, 1990.
78. Levine E, Slusher SJ, Granthan JJ, Wetzel L.H. Natural history of adquired renal cystic disease in dialysis patients: a prospective longitudinal CT study. Am J Roentgenol 156 (3): 501-6, 1991.
79. Truong LD, Krisham B, Cao JT y cols.: Renal neoplasm in adquired cystic kidney disease. Am J Kidney Dis 26 (1): 1-12, 1995.
80. Denton MD, Magee CC, Ovuworie C y cols.: Prevalence of renal cell carcinoma in patients with ESRD pre-transplation: a pathologic analysis. Kidney Int 61 (6): 2201-9, 2002.
81. Grantham JJ: Adquired cystic kidney disease. Kidney Int 40 (1): 143-52, 1991.
82. Marple JT, MacDougall M, Chonko AM: Renal cancer complicating acquired cystic kidney disease. J Am Soc Nephrol 4 (12): 1951-6, 1994.
83. Taylor AJ, Cohen EP, Erickson SJ y cols.: Renal imaging in long-term dialysis patients: a comparison of CT and ultrasonography. Am J Roentgenol 153 (4): 765-7, 1989.
84. Matson MA, Cohen EP: Acquired cystic kidney disease: occurrence, prevalence and renal cancers. Medicine (Baltimore) 69 (4): 217-26, 1990.
85. Llach FY, Bover J: Osteosistrofia renal: clínica, diagnóstico y tratamiento. En: Insuficiencia renal crónica. Eds: Llach y Valderrábano, ediciones Norma, Madrid 321-22, 1997.
86. Ritz E, Prager P, Krepien B: Skeletal x-ray findings and bone histology in patients on hemodialysis. Kidney Int 13: 316-22, 1978.
87. Meema H.E, Rabinovich S, Meema S, Lloyd GJ, Oreopoulos DG: Improved radiological diagnosis of azotemic osteodystrophy. Radilogy 102: 1-10, 1972.
88. Owen J, Parnell A, Keir M, Ellis H, Wilkinson R, Ward M, Elliot R: Critical analysis of the use of skeletal surveys in patients with chronic renal failure. Clin Radiol 39: 578-582, 1988.
89. Mansouri B, Adybeig B, Rayegani M, Yasami S, Behshad V: Uremic neuropathy and the analysis of electrophysiological changes. Electromyogr Clin Neupophysiol 41 (2): 107-15, 2001.
90. Koch KM: Dialysis-related amyloidosis. Kidney Int 41: 1416-29, 1992.
91. Kachel HG, Altameyer P, Bladams CA, Koch KM: Deposition of amyloid-like substance as possible complication of regular dialysis treatment. Contrib Nephrol 36: 127-32, 1983.
92. Hassan K, Amir S, Michael S, Simri W, Haj M, Shassha SM, Kristal B: Electrophysiological abnormalities in upper extremities after brachiocephalic A-V fistulas construction in predialysis patients. Ren Fail 26 (2): 111-7, 2004.
93. Sivri A, Celiker R, Sungur C, Kutsal YG: Carpal tunnel Syndrome: a major complication in hemodialysis patients. Scand J Rheumatol 23 (5): 287-90, 1994.
94. Carrasco-Sánchez FJ, López-Domínguez JM, Casado-Chocan JL, Pérez-Gutiérrez S, Onaindia-Rico JM, Borrero-Martín JJ, Blanco-Ollero A: Uremic myopathy. Rev Neurol 30 (12): 1154-6, 2000.
95. Sobh MA, Sheashaa H, Tantawy AE, Ghoneim MA: Study of effect of optimization of dialysis and protein intake on neuromuscular function in patients under maintenance hemodialysis tratment. Am J Nehrol 18 (5): 399-403, 1998.
96. Porfrey PS, Harnett JD: Cardiac disease in chronic uremia. Pathophysiology and clinical epidemiology. ASAIO 40 (2): 121-9, 1994.
97. Venkatesan J, Henrich WL: Anemia, hypertension and myocardial dysfunction in end stage renal disease. Semin Nephrol 17 (4): 257-69, 1997.
98. Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC: Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 41 (6): 1267-77, 2003.
99. Stack AG, Bloembergen WE: A cross-secional study of the prevalence and clinical correlates of congestive heart failure among incident US patients. Am J Kidney Dis 38 (5): 992-1000, 2001.
100. Middeleton RJ, Parfrey PS, Foley RN: Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 12 (5): 1079-84, 2001.
101. Abergel E, Tase M, Boehlender J, Menard J, Chatellier G: Which definition for echocardiographic left ventricular hypertrophy? Am J Cardiol 75 (7): 498-502, 1995
102. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11 (5): 912-6, 2000.
103. Alpert MA, Ravenscraft MD: Pericardial involvement in endstage renal disease. Am J Med Sci 325 (4): 228-36, 2003.
104. Gunukula SR, Spodick DH: Pericardial disease in renal patients. Semin Nephrol 2 (1) 1: 52-6, 2001.
105. Rutsky EA, Rostand SG: Treatment of uremic pericarditis and pericardial effusion. Am J Kidney Dis 10 (1): 2-8, 1987.
106. Lundin AP: Recurrent uremic pericarditis: a marker of inadequate dialysis. Sem Dial 3: 5-11, 1990.
107. Forman MB, Virmani R, Robertson RM, Stone WJ: Mitral anular calcification in chronic renal failure. Chest 85 (3): 367-71, 1984.
108. Straumann E, Meyer B, Misteli M, Blumberg A, Jenzer HR: Aortic and mitral value disease in patients with end renal failure on long-term haemodialysis. Br Heart J 67 (3): 236-9, 1992.
109. Stinebaugh J, Lavie CJ, Milani RV, Cassidy MM, Figueroa JE: Doppler echocardiographic assessment of valvular heart disease in patients requiring hemodialysis for end-stage renal disease. South Med J 88 (1): 65-71, 1995.
110. Baglin A, Hanslik T, Vaillant JN, Boulard JC, Moulonguet-Doleris L, Prinseau J: Severe valvular heart disease in patients on chronic dialysis. A five year multicenter French survey. Ann Med Interne (Paris) 148 (8): 521-6, 1997.
111. Abrahams C, D́Cruz I, Kathpalia S: Abnormalities in the mitral valvue apparatus in patients undergoing long term hemodialysis. Autopsy and echocardiographic correlation. Arch Intern Med 142 (10): 1796-1800, 1982.
112. Moe SM, O'Neill KD, Resterova M, Fineberg N, Persohn S, Meyer CA: Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 19 (9): 2387-93, 2004.
113. Moe SM, ÓNeill KD, Fineberg N, Persohn S, Ahmed S, Garret P, Meyer CA: Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 18 (6): 1152-8, 2003.
114. Andrés A, Revilla Y, Ramos A, González E, Vereda MS, Praga M, Morales E, Morales JM, Díaz R, Cruceyra G, Aguirre F, Leiva O, Gragera F: Helical computed tomography angiography is the most efficient test to assess vascular calcifications in the iliac arterial sector in renal transplant candidates. Transplant Proc 35 (5): 1682-3, 2003.
115. Medina López RA, Torrubia Romero FJ, Cruz Navarro N, Montanes Medina P: Vascular assessment befote kidney transplantation. Role of computerized helical tomography. Arch Esp Urol 53 (5): 443-6, 2000.
116. Raggi P: Electron beam tomography to image cardiovascular calcifications in hemodialysis patients. J Nephrol 15 (SUPL. 6): S77-81, 2002
117. Marple JT, MacDougall M: Development of malignancy in the end-stage renal disease patient. Semin Nephrol 13 (3): 306-14, 1993.
118. Port FK, Ragheb NE, Schwartz AG, Hawthorne VM: Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis 14 (2): 119-23, 1989.
119. Kantor AF, Hoover RN, Kinlen LJ, McMullan MR, Fraumenti JF. Jr: Cancer in patients receiving long-term dialysis treatment. Am J Epidemiol 126 (3): 370-6, 1987.